China Ranks as a Key Strategic Pillar for Bayer
Bayer, a seasoned participant with seven appearances at the CIIE and an "old friend" of the event, has consistently regarded China as a key strategic market and a major element of its strategic foundations.
TroibNews 
Editor's note: Bill Anderson is CEO of Bayer. The article reflects the author's opinions and not necessarily the views of CN.
From November 5 to 10, the much-awaited 7th China International Import Expo will take place in Shanghai. Serving as a window for China to establish a new development pattern and as a platform for promoting high-level opening, this year’s CIIE theme, "New Era, Shared Future," promises to create new opportunities for countries and regions worldwide.
Bayer, a participant in the CIIE for seven consecutive years, has not only observed the dynamic growth of the Chinese market but has also fostered in-depth communication and collaboration with global partners through this event.
For Bayer, which considers itself an "old friend" of the CIIE, China remains a strategic market. The 7th CIIE presents an excellent opportunity to showcase our innovative products and advanced technology while engaging with a diverse range of partners on this unique platform.
Leveraging the CIIE's "incubator" effect, Bayer has showcased over 100 innovative items, nurtured 8 "CIIE babies," and signed more than 30 major agreements across various sectors in the past six years.
This year, Bayer is emphasizing its bold mission, "Health for All, Hunger for None," while presenting innovations from its three divisions—Pharmaceuticals, Consumer Health, and Crop Science. The company is also exhibiting in two subsections, utilizing a record-high space of 800 square meters.
Since its entry into China, Bayer has made substantial investments in local projects to enhance innovation. Across Pharmaceuticals, Consumer Health, and Crop Science, and from both R&D and market perspectives, China stands as one of Bayer's most critical strategic pillars.
With over 140 years of development in China, Bayer remains steadfast in its commitment to Chinese patients, consumers, and growers. The company plans to further deepen its presence in the country by improving local production capabilities and actively pursuing partnerships with local research institutions and innovative firms. These initiatives are designed to support China's national strategies, including Healthy China, Rural Revitalization, and sustainable development.
Sanya Singh for TROIB News
From November 5 to 10, the much-awaited 7th China International Import Expo will take place in Shanghai. Serving as a window for China to establish a new development pattern and as a platform for promoting high-level opening, this year’s CIIE theme, "New Era, Shared Future," promises to create new opportunities for countries and regions worldwide.
Bayer, a participant in the CIIE for seven consecutive years, has not only observed the dynamic growth of the Chinese market but has also fostered in-depth communication and collaboration with global partners through this event.
For Bayer, which considers itself an "old friend" of the CIIE, China remains a strategic market. The 7th CIIE presents an excellent opportunity to showcase our innovative products and advanced technology while engaging with a diverse range of partners on this unique platform.
Leveraging the CIIE's "incubator" effect, Bayer has showcased over 100 innovative items, nurtured 8 "CIIE babies," and signed more than 30 major agreements across various sectors in the past six years.
This year, Bayer is emphasizing its bold mission, "Health for All, Hunger for None," while presenting innovations from its three divisions—Pharmaceuticals, Consumer Health, and Crop Science. The company is also exhibiting in two subsections, utilizing a record-high space of 800 square meters.
Since its entry into China, Bayer has made substantial investments in local projects to enhance innovation. Across Pharmaceuticals, Consumer Health, and Crop Science, and from both R&D and market perspectives, China stands as one of Bayer's most critical strategic pillars.
With over 140 years of development in China, Bayer remains steadfast in its commitment to Chinese patients, consumers, and growers. The company plans to further deepen its presence in the country by improving local production capabilities and actively pursuing partnerships with local research institutions and innovative firms. These initiatives are designed to support China's national strategies, including Healthy China, Rural Revitalization, and sustainable development.
Sanya Singh for TROIB News
